ArticleMetallomics : integrated biometal science2025
Selective inhibition of NikA mediated Ni(II) import in E. coli by the Indium(III)-EDTA complex.
Article in Metallomics : integrated biometal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nickel is a required nutrient for bacteria to produce [NiFe]-hydrogenase and urease enzymes. [NiFe]-hydrogenase catalyzes the reversible conversion of hydrogen into protons and electrons and urease catalyzes the hydrolysis of urea into carbon dioxide and ammonia-both key in bacterial pathogenesis. As such, nickel trafficking and homeostasis are interesting targets for potential antibacterial strategies. In E. coli, NikA binds a Ni(II)-(L-His)2 chelate in the periplasm and delivers this complex to the NikBCDE transporter. Blocking Ni(II) uptake by NikA would prevent the biosynthesis of active [NiFe]-hydrogenase. Fe(III)-EDTA is a potent ligand for NikA, however due to the potential for reduction of Fe(III) to Fe(II), it has limited utility. Using Fe(III)-EDTA as a starting point for inhibitor design, similar stable complexes of Bismuth(III), Lutetium(III) and Indium(III) were investigated. The In(III)-EDTA complex is a potent inhibitor of cellular [NiFe]-hydrogenase activity (IC50 of 600 μM ± 100 μM) while being nontoxic to bacterial growth. The mechanism of In(III)-EDTA hydrogenase inhibition was confirmed by the inhibition of Ni(II)-dependent processing of HycE (hydrogenase-3), which could be rescued with the addition of exogenous nickel. To elucidate the binding affinity of In(III)-EDTA to NikA, isothermal titration calorimetry (ITC) was carried out, revealing stoichiometric 1:1 binding with a Kd of 17.3 µM ± 3.0 µM. Indium concentrations determined by inductively coupled plasma mass spectrometry in E. coli cells in the presence or absence of NikA showed no discernable difference, further supporting the competitive inhibition of nickel uptake by blocking NikA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.